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Hepatitis A virus receptor blocks cell differentiation and is over-
expressed in clear cell renal cell carcinoma.
Background. The molecular mechanisms underlying tumori-
genesis and progression of clear cell renal cell carcinoma
(ccRCC) are not well understood. We aimed to identify new
molecular markers to provide insight into these processes.
Methods. This work reports on the identification of human
hepatitis A virus cellular receptor 1 (hHAVcr-1) as a differen-
tially expressed gene in ccRCC using RNA-based arbitrarily
primed polymerase chain reaction (RAP-PCR). Results were
further confirmed by Northern and Western blot assays. Car-
cinoma 769-P and normal HK-2 cells derived from proximal
tubule epithelial cells, grown under different culture conditions,
were used to understand the putative role of hHAVcr-1 in renal
malignancy. hHAVcr-1 stable transfected clones and dipeptidyl
peptidase IV (DPPIV) assays allowed assessing its involvement
in cell differentiation.
Results. The hHAVcr-1 is overexpressed in eight out of 13
ccRCC and its expression neglected in benign oncocytomas. In
culture, hhavcr-1 is dramatically overexpressed in normal and
tumor cell lines that, having acquired the fully differentiated
phenotype, are induced to de-differentiate by means of phorbol
ester phorbol 12-myristate-13-acetate (PMA) treatment. Simi-
larly, differentiation prevention by addition of PMA to conflu-
ent cells also increases hhavcr-1 expression. hHAVcr-1 stable
transfected 769-P cells proved that hhavcr-1 itself blocks differ-
entiation. Since hhavcr-1 is expressed at higher levels in tumor
cells, we used an African green monkey cell model to show
that immunotoxins directed against the monkey homologue of
hhavcr-1 could kill kidney cells.
Conclusion. Our results showed that hHAVcr-1 blocks dif-
ferentiation of proximal tubule epithelial cells and that it could
be used as a target for therapy of kidney carcinomas.
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Renal cell carcinoma (RCC) is characterized by the
lack of early warning signs, leading to a high proportion
of patients with metastasis at the time of diagnosis. RCC
is a heterogeneous disease subdivided into clear, pap-
illary, granular, spindle, and mixed cell variants based
on cytoplasmic features [1]. The prognosis of clear cell
RCC (ccRCC), the most malignant and common form
of renal cancer, varies according tumor stage and histo-
logic grade [2]. ccRCC has been extensively studied at
the cytogenetic level [3–6] and numerous studies have
attempted to correlate genetic and biochemical markers
with the development and progression of ccRCC. Molec-
ular changes in sporadic ccRCC include increased expres-
sion of growth promoting genes, loss of cell cycle arrest
and cell death genes, enhanced transcription of genes pro-
moting angiogenesis and numerous genes involved pro-
tein, fatty acid, and carbohydrate metabolism, increased
formation of reactive oxygen species, up-regulation of
genes promoting invasion or metastasis, and increased
expression of genes which inhibit activation of the im-
mune system (reviewed in [7]). Despite this information,
little is known about the underlying biochemical mecha-
nism(s) responsible for the variable severity of ccRCC.
Tumor invasion and metastasis are generally charac-
terized by cell proliferation, cell-cell dissociation and
movement, matrix degradation, and survival due to the
activation of genes involved in these processes (reviewed
in [8]).
To better understand the mechanism(s) of tumorigen-
esis and progression of ccRCC, we studied expression of
mRNAs in ccRCCs compared to their normal matched
tissues using RNA-based arbitrarily primed polymerase
chain reaction (RAP-PCR) [9–13]. We have identified in-
creased expression of the human hepatitis A virus cellular
receptor 1 (hHAVcr-1) gene [14] in ccRCC. The role of
hHAVcr-1 in oncogenic processes, as well as its therapeu-
tic implications, are discussed.
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Table 1. Anatomic-pathologic and clinical details of patients
included in this study
Sample Gender Age years Tumor type Stage Grade
2 M 70 Oncocytoma
25 F 69 ccRCC pT2N0M0 G1
42 M 52 Oncocytoma
45 M 70 ccRCC pT2N0M0 G1
56 M 79 ccRCC pT2N0M0 G3
74 M 52 ccRCC pT3N3M1 G4
76 F 48 Oncocytoma
78 M 73 ccRCC pT2N0M0 G2
79 F 54 ccRCC pT2N0M0 G3
81 M 32 ccRCC pT2N0M0 G3
83 M 54 ccRCC pT2N0M0 G2
86 F 83 Oncocytoma
91 F 70 ccRCC pT3NXMX G3
94 F 53 ccRCC pT2N0M0 G3
95 F 53 ccRCC pT2N0M0 G2
96 F 68 ccRCC pT2N0M0 G1
100 M 56 Oncocytoma
101 F 70 ccRCC pT1N0M0 G1
104 F 73 ccRCC pT3bN0M0 G4
105 F 54 ccRCC PT1N0M0 G1
Abbreviations are: M, male; F, female; ccRCC, clear cell renal cell carcinoma.
METHODS
Samples
Fresh surgical samples of kidney tumors and normal
tissues distant from the tumor were obtained at the time
of surgery at the Departament d’Urologia de l’Hospital
Vall d’Hebron, snap-frozen in liquid nitrogen, and stored
at −80◦C. All tissue samples were obtained from patients
65.1 ± 13.4 years old who had not undergone chemother-
apy or immunotherapy before nephrectomy. The clinical
and anatomic-pathologic characteristics of the samples
are summarized in Table 1. This study was approved by
the Institutional Review Board, and informed consent
was obtained from all patients before surgery.
RAP-PCR
Differential RNA display was performed as described
[13] without modifications.
Northern blotting
Samples containing 15 lg of total cellular RNA were
denatured, fractionated in 1% formaldehyde agarose
gels, and transferred to Zeta-Probe nylon membranes
(Bio-Rad, Hercules, CA, USA). Membranes were hy-
bridized at 42◦C in 50% formamide with cDNA probes la-
beled with a-[32P] deoxycytidimine triphosphate (dCTP)
by random priming (Stratagene, La Jolla, CA, USA).
Chromosomal location of hHAVcr-1
To map hHAVcr-1 on human chromosomes, fluores-
cence in situ hybridization (FISH) was performed using
a 1.3 kb fragment cloned into pGEM-T vector as a probe.
As a control, a centromeric probe from human chromo-
some 5 was used (D5Z1). FISH was performed as de-
scribed elsewhere [15].
Briefly, 2 lg of each probe were labeled with biotin-
16-deoxyuridine triphosphate (dUTP) (huHAVcr-1 frag-
ment) or digoxigenin-11 dUTP (D5Z1) (Roche, Basel,
Switzerland) by a standard nick-translation reaction and
purified by gel filtration. Four hundred nanograms of each
labeled probe was precipitated along with 1 lg of Cot1
DNA (Gibco BRL; Life Technologies, Rockville, MD,
USA) and 1 lg of salmon sperm DNA (Sigma Chemical
Co., St. Louis, MO, USA). The pellet was resuspended
in a hybridization mix containing 50% formamide and
50% [20% dextran sulfate in 12 × standard sodium cit-
rate (SSC)]. Ten microliters of the hybridization mix was
applied to the slide (when hybridizing two probes, 7 lL
of each mix was used instead). After heat denaturation,
slides were incubated overnight in a humid chamber at
37◦C. Posthybridization washes were performed in three
changes of 50% formamide, 2 × SSC at 42◦C, followed
by three changes of 0.1 × SSC at 60◦C. For detection
of the fluorescent signals, slides were incubated at 37◦C
with sheep antidigoxigenin-tetramethylrhodamine isoth-
iocyanate (TRITC) (Roche) and avidin-fluorescein isoth-
iocyanate (FITC) (Vector Laboratories, Burlingame, CA,
USA) for 20 minutes, and then washed in three changes
of 4 ×SSC, Tween 20 at 37◦C. Biotin-labeled probe
was amplified once by incubating the slide first with bi-
otinylated anti-avidin and then, with avidin-FITC. Slides
were mounted with 40 lL of antifade solution (Vector
Laboratories) containing 150 ng/mL of 4,6-di-amidino-
2-phenylindole (DAPI). Slides were studied under an
Olympus (Melville, NY, USA) AH-3 fluorescence mi-
croscope equipped with the appropriate filter set. Im-
ages were analyzed with the Cytovision system (Applied
Imaging, Newcastle Upon Tyne, UK).
Reverse transcription (RT)-PCR/Southern blot analysis
Total RNA was isolated using guanidine thiocyanate as
described elsewhere [16]. For cDNA synthesis and PCR
amplification, 0.5 lg of DNAse I treated total RNA was
reverse-transcribed and amplified using the Super Script
One-Step reverse transcription RT-PCR System (Invit-
rogen Life Technologies, Paisley, UK) in a single step
according to the manufacturer’s instructions. Synthetic
oligonucleotides 5′-CATTGTGAGTGACAGAGCC-3′
and 5′-GGATGAGCCAGTTTTAG-3′ specific for
hHAVcr-1, and 5′-ATGGTCAACCCCACCGTG-3′
and 5′-TTGCAATCCAGCTAGGCATG-3′ specific
for cyclophilin (hCyp) A gene, a template integrity
endogenous marker, were used as amplification primers.
The RT-PCR reactions were performed using a DNA
Thermal Cycler 2400 (Perkin-Elmer, Foster City, CA,
USA) and the following conditions: 30 minutes at 48◦C
(RT) and 2 minutes at 94◦C, 25 cycles of 15 seconds at
94◦C, 30 seconds at 53◦C, and 1 minute at 68◦C, and 7
minutes at 68◦C as a final extension.
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Aliquots of 5 to 10 lL of the amplified products
were fractionated in 1.5% agarose gels, stained with
ethidium bromide, transferred to nylon Zeta-probe
membrane (Bio-Rad), and hybridized to synthetic
oligonucleotides specific for hHAVcr-1 cDNA (5′-
TTGCTCTTTTGGGTGTCATC-3′) and hCyp A (5′-
CACACGCCATAATGGCACTG-3′) end-labeled with
a-[32P]-adenosine triphospate (ATP) (5000 Ci/mmol) us-
ing T4 polynucleotide kinase (Promega, Madison, WI,
USA). After an overnight hybridization, membranes
were extensively washed, and exposed to Hyperfilm
autoradiographic film (Amersham Pharmacia Biotech,
Little Chalfont, Buckinghamshire, UK).
Comparative densitometry analysis
Nonsaturated autoradiographs were analyzed in a Bio-
Rad GS 700 Image densitometer using the Molecular
Analyst Software, version 2.1 (Bio-Rad). To perform an
accurate densitometric quantification, all the bands were
within a linear range setting an upper limit of 2.0 optical
density (OD), to ensure that the analysis was done un-
der nonsaturating conditions. Values higher than 2.0 OD
were considered saturated by the program and were not
used for the calculation of the expression ratios shown in
the figures.
Western blotting
For preparation of cytosol, membrane, and cytoskele-
ton cell fractions, cells were scrapped from the Petri dish
and disrupted on ice in buffer A [25 mmol/L Tris HCl,
pH 7.6, 1 mmol/L ethyleneglycol tetraacete (EGTA), and
10 mmol/L NaCl] containing 1 mmol/L phenylmethylsul-
fonyl fluoride (PMSF) and 25 lg/mL leupeptin using a
Dounce homogenizer. Homogenates were centrifuged at
15,000g for 30 minutes at 4◦C, and the supernatant was
stored as the soluble cytosolic fraction. Pellets were re-
suspended in buffer B (buffer A plus 1 mmol/L PMSF,
25 lg/mL leupeptin, and 1% Triton X-100) by 10 strokes
in a Dounce homogenizer and incubated on ice for 30
minutes. Homogenates were centrifuged under the same
conditions as before, and the supernatants were stored as
the detergent-extracted membrane fraction. Pellets were
resuspended in buffer C [25 mmol/L Tris-HCl, pH 7.6, 0.5
mol/L EGTA, 0.5 mol/L ethylenediaminetetraacetic acid
(EDTA), 1% sodium dodecyl sulfate (SDS), 1 mmol/L
PMSF, and 25 lg/mL leupeptin], boiled for 15 minutes,
and centrifuged for 20 minutes at 4◦C. The supernatant
contained the cytoskeleton fraction. For tissue protein
preparation, we followed the same procedure. Total pro-
tein extracts were obtained by lysing cells and tissues in
buffer C containing PMSF and leupeptin for 15 minutes
at 4◦C. After boiling for 15 minutes, protein extracts were
centrifuged for 20 minutes at 4◦C.
Samples were normalized for protein concentration
using the Bradford assay (Bio-Rad) adjusted for equal
protein levels, and 15 lg of each sample were analyzed
by SDS-12% polyacrylamide gel electrophoresis (PAGE)
under reducing conditions. Proteins were transferred to
a polyvinylidine difluoride (PVDF) membrane (Schle-
icher & Schuell, Keene, NH, USA), blots were blocked
overnight with 5% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS)-0.01% Tween-20, and
incubated with 1:2,500 dilution of rabbit anti-hHAVcr-1
antiserum [14] in the same blocking buffer for 2 hours
at room temperature. After washing extensively with
PBS-0.01% Tween 20, membranes were incubated with
antirabbit horseradish peroxidase (HRP)-conjugated an-
tibody (Dako, Carpenteria, CA, USA) for 1 hour at
room temperature, washed and developed with enhanced
chemiluminescence (ECL) ECL-Plus (Amersham Phar-
macia Biotech). As a protein loading control, the same
filters were stained with Coumassie blue following the
membrane manufacturer’s instructions.
Cell lines, cultures, and reagents
Human renal adenocarcinoma cell lines 769-P (CRL-
1933), 786-O (CRL-1932), A-704 (HTB-45), and
proximal tubule epithelial cell line HK-2 (CRL-2190)
immortalized by transduction with HPV-16 [17] were
obtained from the American Type Culture Collection
(ATCC). 769-P cells were cultured in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 1% L-glutamine, 1% nonessen-
tial amino acids, penicillin (100 U/mL), and streptomycin
(100 U/mL) in 5% CO2. Media for cell culture and
supplements were obtained from Biological Industries
(Beit Haemek, Israel). HK-2 cells were grown in ker-
atinocyte serum–free medium (Invitogen Life Technolo-
gies) supplemented with epidermal growth factor (EGF)
(0.2 ng/mL) and bovine pituitary extract (25 lg/mL). Pri-
mary cultures of normal and tumor renal tissues were
prepared as described [13].
To induce scattering, preconfluent 769-P and HK-2
cells were treated with 50 nmol/L phorbol ester phorbol
12-myristate-13-acetate (PMA) (Sigma Chemical Co.)
for a period of 2 to 48 hours. Proliferation assays were
performed treating with 10 ng/mL EGF (Invitrogen Life
Technologies) and 10 ng/mL insulin-like growth factor-I
(IGF-I) (Sigma Chemical Co.). Cells were first starved of
FBS for 24 hours and treated for varying durations with
growth factors in the presence of 0.5% of FBS. Preconflu-
ent, confluent, and 5- and 10-day postconfluent 769-P cells
were used to study proliferating, nondividing, and differ-
entiating stages. After 10 days of postconfluence, cells
acquired a fully differentiated phenotype, with increased
expression of the differentiation marker villin and dome
formation [13]. To induce dedifferentiation, differenti-
ated cells were treated with PMA for 48 hours. To prevent
differentiation, confluent cells were treated with PMA
for 10 days. Treated and control cells were washed with
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ice-cold PBS and scraped from the Petri dishes with a
rubber policeman. Cell pellets were stored at −80◦C un-
til used.
Transfection assays
Monolayers of 769-P cells grown in 25-cm2 flasks were
transfected with 5 lg of pIRES hk, a plasmid that con-
tains the hHAVcr-1 cDNA [14], or pIRES-1 Hyg vector
(BD Biosciences Clontech, Bedford, MA, USA) using
LipofectAMINE (Invitrogen Life Technologies). After
transfection, cells were trypsinized, seeded into 10 cm2
Petri dishes, and selected with 400 lg/mL of Hygromycin
B (Roche). Three antibiotic c-resistant colonies were iso-
lated using cloning cylinders.
Dipeptidyl peptidase IV (DPPIV) activity assay
Total cell homogenates were prepared by lysing cells in
25 mmol/L Tris-HCl, pH 7.6, 10 mmol/L NaCl, 1 mmol/L
EGTA, and 1% Triton X-100 in a Dounce homogenizer
and incubating at 4◦C for 30 minutes. Lysates were cleared
by centrifugation at 13,000g for 30 minutes at 4◦C. Pro-
tein concentration was determined as described above.
DPPIV (EC 3.4.14.5) activity was measured as described
[18], using glycyl-L-proline-p-nitroanilide (GPNA) as
substrate. Results are expressed as U/mg of protein;
1 unit is defined as the activity that hydrolyzes 1 lmol
of substrate per minute at 37◦C.
Internalization and killing assays
For the internalization assay, African green monkey
kidney (AGMK) clone GL37 cells [18] were grown in 8-
well slides (Nalge Nunc International, Ridderstraat, Bel-
gium). Confluent monolayers were treated at 0◦C with
1 lg/mL anti-hhavcr-1 monoclonal antibody 190/4 [19] or
antihuman a3 integrin monoclonal antibody P1B5 (In-
vitrogen Life Technology) for 30 minutes. After washing
extensively at 0◦C, cell culture growth media was added,
and monolayers were incubated for at 37◦C. At differ-
ent times, cells were fixed with cold acetone at −20◦C for
20 minutes, and stained with rhodamine-labeled goat an-
timouse antibody (Kirkegaard and Perry Laboratories,
Gaithersburg, MD, USA) as suggested by the manufac-
turer. Immunofluorescence micrographs were taken with
a Zeiss Axioscope microscope (Zeiss, Thornwood, NY,
USA) at 1000× with an oil immersion objective.
For the killing assay, 80% confluent GL37 cells mono-
layers grown in 6-well plates (Nalge Nunc International)
containing 0.5 mL of Eagle’s minimal essential medium
(EMEM)-10% FBS (Invitrogen Life Technology) were
treated with 5 lg of purified monoclonal antibodies
190/4 and 5 lg of monoclonal antibody-Zap immuno-
toxin (Advanced Targeting Systems, San Diego, CA,
USA), an affinity-purified goat antimouse IgG conju-
gated with saporin toxin [20]. Control GL37 monolayers
were treated with monoclonal antibody-Zap immuno-
toxin and without first antibody. Cells were incubated
at 37◦C in a CO2 incubator for 3 days and cell survival
was evaluated under an inverted microscope. Monolay-
ers were washed three times with EMEM-10% FBS, and
cells that remained attached to the plastic (surviving cells)
were grown for 7 days in the same dish, trypsinized, and
passed to a 25 cm2 flask.
Cell surface enzyme-linked immunosorbent
assay (ELISA)
Expression of hhavcr-1 in GL37 cells was analyzed by a
cell surface ELISA as described previously [19]. Briefly,
duplicate wells of unfixed cells grown in 96-well plates
were treated with twofold dilutions of monoclonal an-
tibody 190/4 or P1B5 for 1 hour at room temperature,
washed extensively, and treated with a 1:1000 dilution
of affinity-purified peroxidase-labeled antimouse anti-
body for 1 hour at room temperature. After the cells
were washed extensively, 100 lL of the one component
tetramethyl-benzidine (TMB) substrate (Kirkegaard and
Perry Laboratories) was added per well. The reaction
was stopped with 1% HSO4, and absorbance was read at
450 nm. The mean OD450 of duplicate wells plotted ver-
sus the inverse of the antibody dilution gave absorbance
curves that plateau at the lowest antibody dilutions and
had background absorbance levels at the highest dilu-
tions. The plateau absorbance values of naı¨ve GL37 cells
and GL37 cells that survived selection with immunotoxin
were compared in a bar graph.
RESULTS
RAP-PCR
The RAP-PCR technique was performed using RNA
from three different subjects to avoid selection of individ-
ual specific bands. Reproducible bands obtained in three
independent experiments were cut, eluted, and amplified.
Their differential expression was tested by Northern blot
and RT-PCR/Southern blot (see below). Figure 1 shows a
representative experiment from which one band was cut
and was identified as hHAVcr-1.
Overexpression of hHAVcr-1 in RCC
To study hHAVcr-1 differential mRNA expression in
ccRCC, we analyzed pathologically characterized tumor
and control renal samples (Table 1) by RT-PCR/Southern
blot analysis. Figure 2A and C shows that 8 out of 13
ccRCC (patients 56, 78, 79, 81, 91, 95, 104, and 105), ex-
hibited a 2- to 12-fold induction of hHAVcr-1 mRNA
levels in tumors compared to normal matched tissues.
Southern blot analysis of genomic DNA indicated that
the differential expression of hHAVcr-1 in ccRCC was
not due to gene amplification events (data not shown). In
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Fig. 1. Representative result of a RNA-based arbitrarily primed-
polymerase chain reaction (RAP-PCR) analysis of normal (N) and tu-
mor (T) kidney tissues from three different patients. The picture shows
a typical RAP-PCR pattern of bands. Arrowheads indicate the differen-
tial product corresponding to human hepatitis A virus cellular receptor
1 (hHAVcr-1).
sharp contrast to the expression pattern found in ccRCC,
expression of the hHAVcr-1 gene in benign oncocytomes
appeared down-regulated when compared to their nor-
mal kidney (Fig. 2B). hhavcr-1 protein shows the same
pattern of expression than the RNA, that is, overex-
pressed in ccRCC and down-regulated in oncocytomes
(Fig. 2C).
Because ccRCC arises from the proximal tubule and
oncocytomes from the collecting duct, we considered the
possibility that overexpression of HAVcr-1 in ccRCC
could be due to the clonal origin of the tumor rather than
a tumor-related event. Because primary cultures of nor-
mal kidney cells mainly express proximal tubule markers
[21, 22], hHAVcr-1 mRNA levels were determined in nor-
mal and tumor-derived primary cultures. Results shown
in Figure 2D demonstrate that hHAVcr-1 is an oncogenic
marker because its expression is increased in tumor cells
compared to normal cells. These experiments have also
demonstrated that Northern blots are sensitive enough
to detect hHAVcr-1 mRNA in primary kidney cell cul-
tures but not in normal renal tissues (Fig. 2E). In tumors,
hHAVcr-1 was only seen in samples that highly overex-
press the receptor (see fold increase values of samples 78,
79, and 81 in Fig 2A) (Fig. 2E). Because proximal tubule
cells comprise about 5% of total kidney cells [23], our re-
sults also suggest that the receptor is normally expressed
in the proximal tubule.
hHAVcr-1 gene maps to chromosome 5
The genomic organization of hHAVcr-1, deduced from
genomic databases (Fig. 3A), consists of 9 exons and 8
introns that span approximately 38.7 kb. FISH analy-
sis verified that hHAVcr-1 maps to human chromosome
5q31.1–32.2 (Fig. 3B). One hundred chromosomes corre-
sponding to 50 metaphases were analyzed and all results
were consistent. Computational analysis revealed the ex-
istence of a pseudogene in chromosome 19. FISH analysis
did not show hHAVcr-1 specific signal on chromosome
19. It is possible that the absence of the multiple exons
coding for the mucin repeats in the pseudogene could be
responsible for the lack of signal in chromosome 19.
Implication of hHAVcr-1 in scatter, proliferation, and
differentiation processes in 769-P cancer cells
Since hHAVrc-1 mRNA was overexpressed in ccRCC
and because the putative function of the protein is
unknown, we investigated whether this receptor could
be involved in carcinogenic-related processes, including
scattering, cell proliferation, de-differentiation, or cell
adhesion-related events. Therefore, we studied expres-
sion of the hhavcr-1 protein in 769-P cells, a renal carci-
noma cell line which is able to differentiate after reaching
confluency [13].
Scatter. Under standard culture conditions, 769-P cells
grow as a monolayer forming compact cell clusters and
exhibit a polygonal shape. Two hours after the addition
of 50 nmol/L PMA cells at the edges of the colonies be-
came looser, flatter, and had fewer cell-to-cell contacts.
Under similar culture conditions, changes were observed
in HT-29 human intestinal carcinoma cells [24] and in
other cell lines. After treatment with PMA for varying
intervals, we studied the expression of hhavcr-1 by West-
ern blot using anti-hhavcr-1 specific antibodies (Fig. 4A).
A major band of approximately 52 kD, which is similar
to that observed in dog cells transfected with the hhavcr-
1 cDNA [14], reacted with the anti-hhavcr-1 antibodies.
A minor band of 70 kD was also observed. The expres-
sion of hhavcr-1 increased after 6 hours of PMA treat-
ment and remained steady until 48 hours posttreatment.
Distribution of hhavcr-1 in membrane, cytoplasmic, and
cytoskeleton fractions of 769-P cells exposed to PMA
continuosly for 6, 24, and 48 hours was also studied
(Fig. 4B). Densitometric analysis of the blots showed that
levels of hhavcr-1 in the membrane fraction of the cells
were maximal 6 hours after treatment with PMA, and
decreased after 24 to 48 hours (Fig. 4B). This decrement
of hhavcr-1 in the membrane fraction was concomitant
with a moderate increase of hhavcr-1 in the cytosolic
fraction. The net increase of hhavcr-1 in 769-P cells
(Fig. 4A) is mainly due to the membrane-associated pro-
tein at 6 hours of treatment and, to a lesser extent, to the
cytosolic fraction after longer treatment times (Fig. 4B).
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0.1 0.13 0.15 0.15 0.6 0.33 0.31 0.8 0.7 0.45 0.8 0.48
1 0.12 1.8 1.4 1.6 0.16 0.8 0.6 1.8 0.36 0.3 0.87
10 0.9 12 9.3 2.7 0.5 2.6 0.75 2.6 0.8 0.4 1.8
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hCyp A
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hCyp A
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Fold induction
42 76 86 100
B
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ccRCC Oncocytomes
C
M-91
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E
Fig. 2. Expression of to human hepatitis A virus cellular receptor 1 (hHAVcr-1) mRNA in clear cell renal cell carcinoma (ccRCC). Total RNA
was extracted from renal normal (N) and tumoral (T) tissues from the same patient. Patient numbers are indicated on top of each pair of normal
and tumoral lanes. Expression of hHAVcr-1 and cyclophilin A (hCypA), an internal control for RNA integrity and loading, was studied by reverse
transcription-polymerase chain reaction (RT-PCR)/Southern blot analysis. Tissue samples were extracted from patients diagnosed with clear cell
renal carcinomas (A) and oncocytomas (B). (C) Western blot analysis confirmed the overexpression of the receptor at the protein level in clear cell
carcinomas (ccRCC) and the lack of expression in oncocytomas. Expression of hHAVcr-1 mRNA was studied by Northern blot analysis of total
RNA extracted from renal primary normal and tumor cell cultures (D) and from normal and tumor tissues (E). Autoradiographs were analyzed by
densitometry (A and D), and the ratios between hHAVcr-1 and the hCypA internal control gene were calculated as shown under each lane.
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No. Size (bp) Position No. Length (bp)
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Fig. 3. Genomic organization of the to human hepatitis A virus cellular receptor 1 hHAVcr-1 gene according to Genbank databases. (A) The
size, position, and length of the exons and introns are indicated. (B) Fluorescence in situ hybridization (FISH) analysis of hHAVcr-1. Partial
metaphase from peripheral human blood of a control sample showing fluorescent signals of hHAVcr-1 at 5q31.1–32.2 and D5Z1 at the centromere
of chromosome 5.
Altogether, these results demonstrate that treatment with
PMA of 769-P cells provokes an up-regulation of the
hhavcr-1 protein. Because scattering precedes the in-
crease of hhavcr-1, we can not conclude whether this in-
crement is a direct consequence of the PMA treatment,
or regulated by the scatter processes.
Proliferation. To study whether expression of hhavcr-
1 is regulated in proliferation events, preconfluent 769-P
cells were starved of FBS for 24 hours and treated with
10 ng/mL each of EGF and IGF-I for 2, 6, 10, and 24 hours
in the absence of FBS. Higher levels of hhavcr-1 were
detected after 24 hours of treatment (Fig. 4C) mainly in
the membrane-associated fraction (Fig. 4D).
Differentiation. 769-P cells are able to express a differ-
entiated phenotype after culturing for 10 days postcon-
fluence [13]. To monitor the differentiated phenotype of
the cells, we measured the activity of DPPIV, a brush bor-
der associated enzyme widely used as a differentiation
marker in colon and renal cells [25, 26]. DPPIV activity
measured in preconfluent, confluent, and postconfluent
(5 and 10 days) 769-P cells clearly increased with time of
culture (Fig. 5A). Under these culture conditions, no cor-
relation was observed between the differentiation state
and hhavcr-1 expression levels (Fig. 5B). The same results
have been obtained by Northern blot in 769-P and in two
other ccRCC cell lines, 786-O and A-704, which are also
able to differentiate (Fig. 5C) [13].
De-differentiation. Since the loss of the differentiated
phenotype is a key event in carcinogenesis, we studied the
expression of hhavcr-1 in de-differentiated 769-P cells.
Differentiated 769-P cells (10 days of postconfluence)
were able to revert to a more undifferentiated pheno-
type after treatment with PMA for 48 hours as demon-
strated by a decrease in DPPIV activity (Fig. 5E). Under
these conditions we observed a nearly fourfold hhavcr-1
increase in de-differentiated cells in comparison to dif-
ferentiated untreated cells (Fig. 5D).
Expression profile of hHAVcr-1 in scattered,
proliferating, and un/de-differentiated HK-2
normal cells
HK-2 cells, an immortalized proximal tubule epithelial
cell line derived from normal adult human kidney, ex-
press many of the phenotypic and functional properties
of normal kidney cells [17]. To compare whether hhavcr-
1 expression was also increased during scatter, prolifera-
tion, and de-differentiation of normal kidney cells, HK-2
cells were grown and treated under the same conditions
as 769-P cells. Interestingly, hhavcr-1 levels did not change
in HK-2 cells under PMA-induced scattering conditions
(Fig. 6A), or in proliferating cells treated with EGF and
IGF-I (Fig. 6B). In contrast, as observed in 769-P cells,
HK-2 cells showed increased hhavcr-1 levels when differ-
entiated postconfluent cells were de-differentiated with
PMA treatment (Fig. 6C, see lane 8 dp + 48 hours PMA).
A similar increment of the receptor was observed when
differentiation was inhibited by adding PMA from day
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Fig. 4. Expression of to human hepatitis A virus cellular receptor 1 (hhavcr-1) glycoprotein in 769-P renal cancer cells by Western blot analysis. Total
protein extracts (A and C) and subcellular protein fractions (B and D) of 769-P cells treated with phorbol ester phorbol 12-myristate-13-acetate
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membranes, and probed with anti-havcr-1 antiserum. Arrowheads point to two bands of 52 and 70 kD apparent molecular weights that correspond
to hhavcr-1. Coumassie blue staining of the same PVDF membrane was used as a loading control (A and C, lower panels). Blots were analyzed by
densitometry and the ratio of hhavcr-1 to total protein was calculated and shown under each lane (A and C) or represented as bar graphs (B and
D).
1 of confluence to day 10 of postconfluence (10 PMA).
The strong expression of the receptor observed in nor-
mal HK-2 cells in comparison to normal renal tissues is
due to the fact that these cells correspond to a selected
population of proximal tubule cells [17] that are the cells
where the receptor is expressed.
Overexpression of hHAVcr-1 blocks the differentiation
process in 769-P cells
To investigate further whether overexpressed hhavcr-1
in PMA-treated cells was responsible for the inhibition of
differentiation and not a mere consequence of the PMA
treatment per se, we stably transfected 769-P cells with an
expression vector containing the open reading frame of
hhavcr-1 cDNA, and correlated hhavcr-1 levels with dif-
ferentiation capacity of transfected clones (Fig. 7). Three
independent cell clones HAVR-1, -2, and -3 were chosen
because they expressed higher hhavcr-1 levels than 769-P
cells transfected with the pIRES empty vector (Fig. 7A).
Interestingly, 769-P pIRES cells, but none of the trans-
fected HAVR-1, -2, and -3 clones were able to differenti-
ate as demonstrated by DPPIV activity (Fig. 7B). The
inverse relationship observed between augmented
hhavcr-1 expression and low DPPIV activity indicates
that this receptor is involved in processes that inhibit dif-
ferentiation in cells derived from renal proximal tubule
epithelia.
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Fig. 5. Expression of to human hepatitis A
virus cellular receptor 1 (hhavcr-1) during dif-
ferentiation of 769-P cells. Dipeptidyl pepti-
dase IV (DPPIV) activity (A) and Western
blot analysis (B) of 769-P cells at precon-
fluent (p), confluent (c), and 5-day or 10-
day postconfluence. Membranes were probed
with anti-havcr-1 antibody. Coumassie blue
staining shows the protein amount loaded
onto each lane. (C) Northern blot analysis
of 786-O and A-704 renal cancer cell lines
showing no changes in hHAVcr-1 mRNA ex-
pression at different stages of confluence. (D)
Western blot analysis of hhavcr-1 expression
(arrowhead) in cells grown at 8 days of post-
confluence treated with phorbol ester phorbol
12-myristate-13-acetate (PMA) for 48 hours
to induce de-differentiation (8 dp + 48 hours
PMA) or without PMA (c10 dp). Ratios of
densitometric analysis are shown at the bot-
tom of the figure. (E) DPPIV activity of 769-P
cells in the same conditions as in (C).
Targeting HAVcr-1 for tumor therapy
Our data indicated that hhavcr-1 is a marker for
ccRCC; therefore, we hypothesized that it could be used
as a target for tumor therapy. To test our hypothesis, we
used an AGMK cell model derived from the GL37 clone
that expresses high levels of havcr-1 [19], the monkey ho-
mologue of hhavcr-1 [14] (Fig. 8). Monoclonal antibody
190/4 binds to havcr-1 and protects GL37 cells against
hepatitis A virus infection. Since monoclonal antibodies
against hhavcr-1 are not currently available and mono-
clonal antibody 190/4 does not react with hhavcr-1, we
used this reagent to determine whether havcr-1 was in-
ternalized into cells. GL37 cells were stained at 0◦C with
monoclonal antibody 190/4 (Fig. 6A and B) or control
monoclonal antibody P1B5, which binds to a3 integrin
expressed at the cell surface of AGMK cells (Fig. 8C
and D). After washing extensively at 0◦C, cells were in-
cubated for different times at 37◦C and fixed with cold
acetone. Internalization of the bound monoclonal an-
tibodies was followed by staining with antimouse anti-
body conjugated with rhodamine and analyzed under a
fluorescence microscope. Prior incubation, both mono-
clonal antibodies stained the cell surface (Fig. 8A and C)
but, after 12 hours of incubation at 37◦C, monoclonal
antibody 190/4 predominantly stained an intracellular
compartment adjacent to the nuclei (Fig. 8B), whereas
monoclonal antibody P1B5 continued to stain the cell sur-
face (Fig. 8D). Low levels of staining of the perinuclear
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compartment by monoclonal antibody 190/4 were ob-
served after 5 minutes of incubation at 37◦C (data not
shown) and reached a maximum after 12 hours of incu-
bation at 37◦C. These results indicated that havcr-1 was
rapidly internalized whereas the integrin detected by
monoclonal antibody P1B5 remained mostly at the cell
surface.
Indirect immunotoxins, consisting of secondary anti-
bodies conjugated with toxins, have been used to kill tu-
moral cells [27]. Therefore, we used monoclonal antibody
190/4, an antimouse antibody conjugated with the toxin
saporin, as a secondary antibody to attempt to kill GL37
cells via the havcr-1 receptor. After 3 days of treatment
with monoclonal antibody 190/4, almost all the GL37
cells treated with monoclonal antibody 190/4 were dead
(>99%), whereas the mock-treated cell remained alive
without presenting signs of cytotoxicity. These results
clearly showed that havcr-1 could be used as a target for
killing tumoral cells. The few surviving GL37 cells were
able to grow in cell culture medium without monoclonal
antibody 190/4 and the immunotoxin. Cell surface ELISA
(Fig. 9) showed that the surviving cells expressed low lev-
els of the 190/4 epitope and similar levels of the P1B5
control epitope compared to naı¨ve GL37 cells. These re-
sults indicate that the GL37 cells that survived treatment
with monoclonal antibody 190/4 plus the immunotoxin
expressed low levels of havcr-1 at the cell surface, and sug-
gest that normal cells that express low levels of hhavcr-1
will be less susceptible to killing via havcr-1.
DISCUSSION
Microarray techniques have identified novel molecular
markers that could be useful in the differential diagnosis
of renal cell carcinoma and to monitor disease progres-
sion and recurrence [28–30]. These molecular studies re-
vealed altered patterns of expression in most ccRCCs
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Fig. 8. Internalization of to hepatitis A virus cellular receptor 1 (havcr-1), the monkey homolog of hhavcr-1. African green monkey (AGMK)
clone GL37 cells were treated with anti-havcr-1 monoclonal antibody 190–4 (A and B) or anti-integrin monoclonal antibody P1B5 (C and D)
for 30 minutes at 0◦C. After washing extensively, cells were incubated at 37◦C for 0 hours (A and C) or 12 hours (B and D) and fixed with cold
acetone. Cells were stained with goat anti-mouse antibodies conjugated with rhodamine and observed under an immunofluorescence microscope
Zeiss Axioscope using a 100× immersion objective.
that could play a role in malignant transformation. Nev-
ertheless, molecular and cellular changes leading to the
development of ccRCC are still not well understood.
Neoplastic markers of renal carcinomas must be defined
to characterize the state of the disease and to serve as
candidate targets for therapeutic agents.
Using a differential gene expression approach, we have
successfully identified altered expressed genes in ccRCC
[13]. In this study, we observed that hhavcr-1, an integral-
membrane mucin-like glycoprotein of unknown natu-
ral function, is up-regulated in a subset of ccRCC and
down-regulated in oncocytomas. Our data, showing that
hHAVcr-1 expression increases in primary cultures of
normal kidney tissues, supports the notion that the pro-
tein is expressed in proximal tubule renal epithelia, the
origin of ccRCC. Moreover, Han et al [31] have demon-
strated that kidney injury molecule-1 (KIM-1), a splicing
variant of hhavcr-1 which only differs in its cytoplas-
mic tail, is specifically expressed in proximal tubule cells
in kidneys during acute tubular necrosis (ATN). Down-
regulation of hHAVcr-1 in oncocytomas might be related
to the fact that the collecting duct where these tumors
originate, does not express the receptor.
The mechanisms underlying hHAVcr-1 overexpression
in ccRCC are not completely understood. One possible
explanation is the duplication of 5q chromosome seen in
60% of ccRCC [32–34], which has been further mapped
to two distinct regions, one at band 5q22 and another
at chromosome band 5q31.1 in 62 sporadic nonpapillary
renal cell carcinomas [35]. Because hHAVcr-1 has been
mapped precisely to the 5q31.1–32.3 site there is a strong
correlation between the frequency of this allelic duplica-
tion and overexpression of the hHAVcr-1 gene identified
in 60% of the tumors analyzed in this study. Furthermore,
alterations in transcriptional control, mRNA processing,
mRNA export and/or stability might contribute as
well.
Overall, the chromosomal location of hHAVcr-1 gene,
its cell-specific expression in normal proximal tubule ep-
ithelia, and its overexpression in ccRCC strongly impli-
cate this receptor in the development of renal-cell tumors.
The involvement of hhavcr-1 in de-differentiation pro-
cesses is one of the most remarkable findings is this
study. Our conclusion has been based on the obser-
vations that 769-P and HK-2 cells overexpress hhavcr-
1 when differentiation is blocked or reverted in the
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presence of PMA. Blocking of differentiation with con-
comitant decrease of villin and DPPIV differentiation
markers in HT-29 colon cancer cells has also been de-
scribed [36]. This relationship between PMA addition,
overexpression of the receptor, and inability to differ-
entiate prompted us to investigate whether hhavcr-1 up-
regulation caused this phenomenon or was merely the
consequence of the phenomenon. 769-P cells stably trans-
fected with hHAVcr-1 have shown that, by itself, over-
expressed receptor is able to prevent differentiation of
proximal tubule-derived cells. Additional members of
this family of receptors have been identified and also
associated with differentiation/de-differentiation events.
Recently, mouse orthologs of hHAVcr-1, termed TIM-
1, -2, and -3, have been implicated in the determination
and regulation of the T-helper cell response by influenc-
ing T-helper differentiation and cytokine production, as
asthma susceptibility genes [37]. The expression of KIM-
1, the rat ortholog of hHAVcr-1, is up-regulated in regen-
erating proximal tubule epithelial cells, which are those
undergoing de-differentiation, proliferation, and scatter-
ing, to repair and regenerate the damaged region of the
nephron in the postischemic kidney [38]. In summary, our
results support the notion that in three different systems,
mouse immune system, regenerating rat kidney, and hu-
man ccRCC, hhavcr-1 plays a role in de-/differentiation
phenomenon.
PMA induces cell colony scattering by decreasing cell-
to-cell contacts, a process already related to increased
invasiveness of epithelial cells [39], in HT-29 colon can-
cer cells [24]. Although PMA was able to induce scat-
tering in normal and tumor cells after 2 hours of treat-
ment, only 769-P tumor cells showed increased hhavcr-1
expression levels after 6 hours of PMA addition. This re-
sult suggests that hhavcr-1 could be involved, not only in
de-differentiation processes, but also in invasiveness and
metastasis. Bailly et al [40] have reported that human
KIM-1 sheds its ectodomain into the extracellular milieu
by a proteolytic cleavage mediated by metalloproteinases
in 769-P and HK-2 cells. This release is enhanced after in-
cubating 769-P cells in PMA 15 minutes [40]. Taking to-
gether, these data indicate that PMA induced shedding
precedes scattering and that overexpression of the recep-
tor could be a consequence of shedding, scatter, or both.
Since ectodomain shedding has been reported for a num-
ber of adhesion molecules and shedding can also promote
adhesion, KIM-1 has been proposed as a putative adhe-
sion protein [40]. The mucin domain of hhavcr-1 confers
a mucin-like role to this protein. Mucins and adhesion
molecules are interrelated proteins involved in metastatic
processes. For instance, the interaction between MUC1
and intercellular adhesion molecule-1 (ICAM-1), an ad-
hesion molecule of the endothelium, could be critical to
the process of metastasis in breast cancer [41]. MUC1
overexpression inhibits integrin-mediated cell adhesion
to extracellular matrix components thereby promoting
invasion and metastasis [42]. The effect of hhavcr-1 on
cell attachment has been tested in different cellular matri-
ces using stably transfected hhavcr-1 clones. None of the
three clones improved attachment to laminin, fibronectin,
or collagen matrices (results not shown) indicating that
hhavcr-1 induce cell detachment rather than tightening
cells to the extracellular matrix. Nevertheless, because
of its functions as a putative adhesion molecule and a
mucin-like protein, together with its overexpression in
scattering and proliferating cells, and its involvement in
de-differentiation, hhavcr-1 is likely to play an important
role in tumor metastasis and invasion.
In addition to the involvement of hhavcr-1 in different
molecular mechanisms that lead to the development of
the malignant phenotype, we have also shown that im-
munotoxins against the monkey homolog of havcr-1 can
kill kidney cells that overexpress this receptor, indicating
that havcr-1 could be a target molecule for therapy of kid-
ney tumors. Han et al [31] have described that shedding
of the receptor also occurs in vivo, based on detection of
the ectodomain in the urine of patients with ATN. There-
fore, detection of the hhavcr-1 ectodomain in the urine
of ccRCC patients may be an important biomarker for
early detection of this disease.
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